Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

This Phase II trial is testing whether low-dose capecitabine (an oral chemotherapy pill) is effective in women with advanced HER2-negative breast cancer — including both hormone receptor-positive and triple-negative subtypes — who have already received at least one prior treatment. **You may be eligible if...** - You are a woman with confirmed breast cancer that is HER2-negative - Your cancer is metastatic or locally advanced with at least one measurable tumor - You have received at least one prior treatment (hormone therapy or chemotherapy) for metastatic disease - Your overall health is adequate (ECOG 0–2) - Your blood counts, liver, and kidney function meet minimum thresholds **You may NOT be eligible if...** - You have HER2-positive breast cancer - Your creatinine clearance is below 30 mL/min (significant kidney impairment) - You are male - You are pregnant or breastfeeding - You have had prior treatment with capecitabine or fluorouracil that caused serious side effects Talk to your doctor to see if this trial is right for you.